UNSPSC 41131718: Fetal hemoglobin assay

In this classification a fetal hemoglobin assay is a device that is used to determine the presence and distribution of fetal hemoglobin (hemoglobin F) in red cells or to measure the amount of fetal hemoglobin present. The assay may be used to detect fetal red cells in the maternal circulation or to detect the elevated levels of fetal hemoglobin exhibited in cases of hemoglobin abnormalities such as thalassemia (a hereditary hemolytic anemia characterized by a decreased synthesis of one or more types of hemoglobin polypeptide chains).

The hemoglobin determination may be made by methods such as electrophoresis, alkali denaturation, column chromatography, or radial immunodiffusion US FDA regulates Fetal hemoglobin assay under 21 CFR 864.7455 and under FDA product code KQI.

UNSPSC 41131718 Fetal hemoglobin assay, a Commodity code, does not align with the recent state and local opportunities tagged under it. The nine posted solicitations span offender drug testing (five-panel and six-panel immunoassay screening with LC/MS/MS confirmation), urinalysis testing for family treatment courts, clozapine assay kits for psychiatric monitoring, forensic drug reference standards, employment physicals and drug testing, employment screening services, breath alcohol testing equipment, and naloxone procurement—none of which involve fetal hemoglobin assay or related pediatric hematology testing. The mismatch suggests either a tagging error in the source data or that the code is dormant for current state and local procurement activity. State and local buyers posting under this code are primarily county community supervision departments, county health and human services divisions, state health agencies, and city college systems across Texas, Oregon, Florida, Nevada, and Illinois.

No state or local procurement activity directly related to fetal hemoglobin assay—the nominal scope of UNSPSC 41131718—appears in the recent opportunities block. The code shows no relevant recent solicitations and should not be pursued based on current market signals.